revealed the combination of azacitidine plus durvalumab (a PD-L1 inhibitor) leads to up to 89.5% grade 3-4 hematologic adverse events (AEs) in higher-risk MDS, while the incidence of grade 3-4 AEs remains 68.3% in patients treated with single azacitidine (39). The gene discussed is CD274; the disease is myelodysplastic syndrome.